Loading
A phase 2 trial of Epcoritamab, Lenalidomide, Ibrutinib in hodgkin lymphoma and non-hodgkin lymphoma, run by Genmab, active and no longer recruiting.
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma is a phase 2 interventional study registered as NCT05283720 by Genmab, with 264 participants enrolled, started 2022-06-14 and due to reach its primary completion in 2032-11. Interventions recorded: Epcoritamab, Lenalidomide, Ibrutinib, Rituximab, Cyclophosphamide. Conditions listed: Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Epcoritamab, Genmab, Prednisone, Rituximab.
Shares Epcoritamab, Genmab, Prednisone, Rituximab.
Shares Epcoritamab, Genmab, Lenalidomide, Prednisone.
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
Shares Epcoritamab, Genmab, Prednisone, Rituximab.
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
Shares Genmab, Lenalidomide, Prednisone, Rituximab.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/